Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ · Healthcare · Biotechnology
Profile
Alnylam Pharmaceuticals, Inc.
- Exchange
- NASDAQ
- Ticker
- ALNY
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
Key facts
Alnylam Pharmaceuticals, Inc.: key facts
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a Biotechnology company in the Healthcare sector.
- In fiscal 2025, Alnylam Pharmaceuticals, Inc. reported revenue of $3.7B and net income of $313.7M.
- Revenue grew 44.8% a year over the last 4 fiscal years.
- Free cash flow was positive in 2 of the last 5 fiscal years.
- Net income was positive in 1 of the last 5 fiscal years.
- Over the last twelve months, revenue was $5.0B and net income was $2.7B.
MonkScore
Alnylam Pharmaceuticals, Inc.'s MonkScore
MonkScore
MonkScore range: 60–70
as of October 2026
Sector rank: 227 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth90–100
- Profitability90–100
- Quality30–40
- Market Conviction30–40
- Safety20–30
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Alnylam Pharmaceuticals, Inc.'s annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $5.0B | $3.7B | $2.2B | $1.8B | $1.0B | $844.3M |
| Gross profit | $3.9B | $3.0B | $1.9B | $1.5B | $868.6M | $704.1M |
| Operating income | $977.6M | $501.6M | -$176.9M | -$282.2M | -$785.1M | -$708.7M |
| Net income | $2.7B | $313.7M | -$278.2M | -$440.2M | -$1.1B | -$852.8M |
| Operating cash flow | $650.4M | $524.1M | -$8.3M | $104.2M | -$541.3M | -$641.7M |
| Capital expenditure | -$149.6M | -$58.7M | -$34.3M | -$62.2M | -$72.1M | -$76.4M |
| Free cash flow | $500.7M | $465.4M | -$42.6M | $41.9M | -$613.3M | -$718.1M |
| Total debt | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $997.6M |
| Cash | $1.8B | $1.7B | $966.4M | $812.7M | $866.4M | $820.0M |
Revenue growth a year
- 1-year
- 65.2%
- 3-year
- 53.0%
- 4-year
- 44.8%
Compound growth between fiscal years.
Peers
Similar companies
- Shattuck Labs, Inc.NASDAQ:STTKMonkScore range: 60–70
- Krystal Biotech, Inc.NASDAQ:KRYSMonkScore range: 70–80
- Aurinia Pharmaceuticals Inc.NASDAQ:AUPHMonkScore range: 70–80
- IDEAYA Biosciences, Inc.NASDAQ:IDYAMonkScore range: 70–80
- ADMA Biologics, Inc.NASDAQ:ADMAMonkScore range: 70–80
- Fortrea Holdings Inc.NASDAQ:FTREMonkScore range: 70–80
- Vertex Pharmaceuticals IncorporatedNASDAQ:VRTXMonkScore range: 70–80
- OmniAb, Inc.NASDAQ:OABIMonkScore range: 70–80
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.